Diabetes Devices Market Going to Rake US$66,053.1 Mn by the end of 2025

Transparency Market Research observes that the competitive landscape in the diabetes devices market is moderately consolidated. Some of the leading companies in this market are Medtronic plc, Eli Lilly and Company, Sanofi S.A., F. Hoffmann-La Roche Ltd, and Novo Nordisk A/S. Most of these companies are focusing on expanding their business in developing parts of the world to tap into the wide consumer base. Furthermore, developing and commercializing diabetes devices that are simple yet affordable will be a winning strategy of these players in the near future.

According to the research report, the global diabetes devices market is expected to be worth US$66,053.1 mn by the end of 2025 from US$37,220.8 mn in 2016. During the forecast period of 2017 and 2025, the global market is expected to rise at a CAGR of 6.7%. Out of the wide range of products to manage diabetes, the global market is likely to be driven by glucose monitoring devices and the products available under this segment. As of 2016, the blood glucose meters held a share of 59.1% in terms of revenue in the global market. Geographically, the global market is dominated by North America due to higher awareness about the disease.

Browse Full Research Report: https://www.transparencymarketresearch.com/diabetes-devices-market.html

The global diabetes devices market is primarily being driven by the soaring diagnostic rate of diabetes across the globe. The high occurrence of this disease is attributable to the highly sedentary lifestyles, excessive stressful living, poor dietary choices, and high alcohol consumption. The improving rate of diagnoses has also led to increased uptake of diabetes devices in recent years. Furthermore, affordable price of devices such as self-monitoring blood glucose meters, lancets, testing strips, and continuous monitoring devices are have also had a positive influence on the overall market. The analysts state the growing awareness about way to manage the disease better is also projected to spike the demand in the global market.

Rise in the number of diabetics due to occurrence of conditions such as jaundice, dengue, pregnancy, and old age has also created a spur in the demand of diabetes devices. Thus, a large pool of patients is projected to fuel market growth in the near future. Growing investments in developing better home diagnostic machines and efficient solutions are expected to generate greater revenues. Convenience of using these devices enabled by their simple design has also been identified as a key market growth for the global market. Thus, the ability to make a safer and effective diagnosis of diabetes is expected to benefit the vendors in the global market.

On the downside, the global market is being affected by the lack of awareness about diabetes and its management in the rural parts of the world. The poor rate of knowledge and low rate of inclination to treat the disease has created a major negative impact on the overall market. Furthermore, diabetes devices continue to be unaffordable to several patients in the low-income category. Thus, the relative high cost of these devices and treatment coupled with lack of reimbursement issues is likely to hamper the market growth.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research

State Tower,

90 State Street, Suite 700,

Albany NY – 12207

United States

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Advertisements

Glycated Hemoglobin Testing Market Will Rake US$ 705 Mn by the end of 2026

Increasing incidences of diabetes have propelled the need for improved diagnostics in the global healthcare devices. Companies manufacturing critical diagnostic devices are focusing on facilitating products for effective tests. The use of glycated hemoglobin in diagnosis of diabetes mellitus continues to gain traction, creating a steady demand for glycated hemoglobin testing. Transparency Market Research’s recent report on the global glycated hemoglobin testing market delivers a forecast outlook on growing demand for these tests in diagnosis of prevalent disorders such as diabetes.

According to the report, the global market for glycated hemoglobin testing is expected to be worth US$ 705 Mn by the end of 2026. During the forecast period, 2017-2026, the global glycated hemoglobin testing market is expected to expand at a CAGR of 8.8%. Leading manufacturers of medical devices are anticipated to be key participants in the global expansion of the glycated hemoglobin testing market. Companies namely, Siemens Healthcare, Bio-Rad Laboratories, Arkray, Ceragem Medisys, Bayer, Chek Diagnostics, DiaSys Diagnostic Systems, Daiichi Biotech, Diazyme Laboratories, Erba Mannheim, EKF Diagnostics, Human Diagnostics, Menarini, Lite-On Technology, Mindray Medical, TaiDoc Technology, Sebia, Randox Laboratories, Trinity Biotech, and Tosoh Bioscience are expected to be observed as leading manufacturers of devices used in glycated hemoglobin tests.

Browse Full Research Report: https://www.transparencymarketresearch.com/glycated-hemoglobin-testing-market.html

Key findings from the report reveal that the global market for glycated hemoglobin testing will witness a significant traction in demand for laboratory based tests. While patients are actively opting for point-of-care glycated hemoglobin testing, laboratories continue to be the key medium where these tests can be executed effectively. In 2017, more than US$ 240 Mn worth of revenues are anticipated to be procured in the global glycated hemoglobin testing market from laboratory based tests. The study also projects that by the end of 2026, point-of-care glycated hemoglobin tests will account for over one-fourth revenue share of the global market.

A regional analysis on the global glycated hemoglobin testing market has been provided in the report. Increasing presence of diabetics in the US and Canada has been observed as the governing factors for fuelling the growth of the glycated hemoglobin testing market in North America. In the overall glycated hemoglobin testing market, North America is expected to dominate in terms of global revenue share. In 2017, the glycated hemoglobin testing market in North America is estimated to be worth over US$ 110 Mn. Meanwhile, the demand for these tests is also expected to gain traction in Europe and the Asia-Pacific excluding Japan (APEJ) region. Improving healthcare infrastructure and diabetic dietary lifestyles of consumers in these regions are observed as the superficial factors driving the growth of glycated hemoglobin testing market in Europe and the APEJ region.

On the basis of techniques, glycated hemoglobin tests can be carried out through immunoassays and chromatography, among others. In 2017, the sales of devices in the global glycated hemoglobin testing market for chromatography and immunoassay techniques are estimated to showcase near-equal revenue share. Moreover, the use of these techniques will depend largely upon the end-use of glycated hemoglobin tests. Hospitals are anticipated to emerge as the largest end-users in the global glycated hemoglobin testing market. In terms of revenues, the end-use of glycated hemoglobin testing in hospitals is expected to rake in US$ 275 Mn globally by the end of 2026. Diagnostic centers are also estimated to emerge as leading end-users of glycated hemoglobin testing in the global market.

Transcriptomics Technologies Market Will Rake US$4.6 Bn by the end of 2019

Transparency Market Research, a global market intelligence consultancy, has published a market study on the global transcriptomics technologies market for the 2013-2019 period. According to this report, the global transcriptomics technologies market will rise at a CAGR of 15.90% from 2013 to 2019 to reach a valuation of US$4.6 bn by the end of the forecast period. The market’s valuation in 2012 was US$1.65 bn. The report is titled “Transcriptomics Technologies Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”.

The report says that the global transcriptomics technologies market will witness substantial growth in the coming years due to several reasons. Transcriptomics research involves studying the structure and function of RNA present in a cell.Presently, transcriptome analysis of several organisms is assisted using next-generation sequencing platforms in the preliminary phase followed by polymerase chain reactions, gene regulation technologies, and microarrays in the latter part. The coalition of these technologies is used for drug discovery, clinical diagnosis of diseases, medical research, and others. With the ever-increasing demand for targeted therapeutics and continual improvement of healthcare infrastructure, the commercial usage of transcriptomics technologies holds promise. Transcriptomics research allows the development of newer therapeutics and diagnostics and further advancement of the existing line of treatment for medical conditions.

Browse Full Research Report: https://www.transparencymarketresearch.com/transcriptomics-technologies-market.html

The report says that in the transcriptomics technologies market, the key application segments undergo consistent development in order to offer added value to users. For instance, the utilization of transcriptomics technologies has benefitted the pharmaceutical and biotechnology fields; other fields are also deriving the advantages of this technology for mutual benefits of both the technology and the application field. Laboratories attempting to use biomarkers and newer gene sequencing methods is an example of this.

The need for the development of adequate equipment in healthcare organizations and laboratories, the growing awareness about transcriptomics technologies globally, and increased participation of government bodies in transcriptomics research are some other factors driving this global market.

However, growth of the transcriptomics technologies market is hampered due to certain factors cited in this report. These include the unavailability of advanced equipment needed for biological computation, unavailability of services essential to analyzing complex information, and an overall deficit of technicians that have expertise in the subject.

The report divides the global transcriptomics technologies market into the regional segments of North America, Asia Pacific, Europe, and Rest of the World. Among the regional segments, Asia Pacific will exhibit a substantial uptake of these technologies and the fastest growth rate in the transcriptomics technologies market during the forecast period. Ongoing infrastructural development for improved healthcare and increased acceptance of novel biotechnology research are the reasons for this.

In 2012, North America led the global transcriptomics technologies market, contributing more than 35% of the revenue in the global market. The presence of advanced healthcare infrastructure, which includes well-equipped research facilities, increased awareness of biotechnology research, and the high number of initiatives taken by governments to promote research activities are the reasons for the dominant position of North America in this market.

The report mentions the top players that operate in the global transcriptomics market. These are Life Technologies Corporation, F-Hoffmann La Roche Ltd., Thermo Fisher Scientific, Illumina Inc., Agilent Technologies, and Affymetrix Inc.

Companion Diagnostics Market Will Rake US$5.6 Bn by the end of 2019

A new Transparency Market Research report states that the global companion diagnostics market stood at US$1.8 bn in 2013 and is predicted to reach US$5.6 bn by 2019. It is predicted to expand at a whopping CAGR of 18.0% between 2013 and 2019. The title of the report is “Companion Diagnostics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.”

As per the report, the increasing demand for personalized medicines is the key factor fuelling the growth of the market for companion diagnostics. In addition, the rising occurrence of cancer globally and the reducing costs of drug development are also augmenting the growth of the market.

Factors such as the rising focus on targeted therapies and the focus of pharmaceutical companies on the in-house advancement of companion diagnostics are also augmenting the growth of the market. Furthermore, the increasing new indication areas have emerged as a key opportunity in the market.

Browse Full Research Report: https://www.transparencymarketresearch.com/companion-diagnostics-market.html

On the other hand, the increasing duration of the approval process and the prolonged development time of companion diagnostics may impede the growth of the market in forthcoming years. The unfavorable reimbursement scenario globally may also have a negative impact on the growth of the market in the coming years, as stated in this report.

Companion diagnostics are various procedures or tests utilized by healthcare professionals in making enhanced treatment decisions for patients as per the patients’ response to particular ongoing treatments. Companion diagnostics aid a health care professional to determine the effects of a specific therapeutic product on patients and any potential risks or side effects associated with its usage. The healthcare professional then adjusts his treatment to achieve enhanced effectiveness and safety.

On the basis of indication, the report segments the companion diagnostics market into lung cancer, breast cancer, gastric cancer, colorectal cancer, melanoma, and others including HIV and thalassemia. Amongst these, in 2012, the segment of breast cancer led the market on the basis of revenue. However, in forthcoming years, the segment of lung cancer will dominate the market, expanding at a CAGR of more than 20% between 2013 and 2019. This is owing to the discovery of myriad relevant companion diagnostics as well as the discovery of lung-cancer-specific biomarkers.

In terms of geography, the report segments the market into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, in 2012, the market for companion diagnostics was dominated by the region of North America and this region held a share of over 35% in the market on the basis of revenue. This is because of the increasing consumer base due to the increasing count of cancer patients, rising affordability, increasing awareness about personalized healthcare, and the presence of sophisticated medical equipment in this region. On the other hand, the increased adoption of innovative medical procedures, the rising disposable incomes of consumers, and the rising healthcare infrastructure will also fuel the Latin America and Asia Pacific companion diagnostics markets.

According to the study, the chief players operating in the market are Roche Holdings AG, Qiagen N.V., Agilent Technologies, Inc., Agendia N.V., Abbott Laboratories, Genomic Health, Inc., GE Healthcare Ltd., and Life Technologies Corporation, among others.

Automated Immunoassay Analyzers Market Will Rake US$3.78 Bn by the end of 2025

Only a handful of companies such as bioMerieux, Inc., Abbott Laboratories, and Roche Diagnostics enjoy stronghold in the global automated immunoassay analyzers market. The lead of the companies is attributable to their expansive regional footprint and product portfolio, finds Transparency Market Research (TMR) in a new study. Furthermore, with a strong financial muscle, these companies are looking toward brighter prospects in the near future. As these companies gear to emerge at the fore, the global automated immunoassay analyzers market may witness roll out of novel products. Besides this, customization of existing products is on cards well. Riding on these factors the global automated immunoassay analyzers market is forecast to showcase robust expansion in the coming years.

TMR has pegged the global automated immunoassay analyzers market at US$2.57 bn in 2016. Exhibiting a steady 4.5% CAGR between 2017 and 2025, the market is expected to reach US$3.78 bn by the end of 2025. During the course of this forecast period, Asia Pacific is likely to exhibit the highest CAGR of 4.9%. Among key end users, the market is expected to witness rising demand from diagnostic laboratories across the world.

Browse Full Research Report: https://www.transparencymarketresearch.com/automated-immunoassay-analyzers-market.html

Proliferation of Laboratory Consolidation to Enable Market Report Positive Trajectory

The accelerated pace of gains witnessed in the market is aided by diverse factors. For instance, the rising incidence of chronic ailments and disease epidemics such as hepatitis infection, Zica, and HIV are among the chief factors fuelling the demand for automated immunoassay analyzers. The market is also expected to gain from the prevailing trend of preventive healthcare and laboratory consolidation. These trends have stoked the demand for laboratory automation and integration, in turn creating a landscape filled with opportunities for the global automated immunoassay analyzers market. With the demand for result comparability and international standardization scaling high, the use of automated immunoassay analyzers is likely to increase in the forthcoming years.

On the back of rising adoption of advanced technologies, the global automated immunoassay analyzers market is expected to expand considerably in the coming years. While in developed nations, the market will remaining steady, growth is likely to pace up in emerging nations. Besides rising disposable income of consumers, favorable government initiatives and investment toward betterment of the healthcare infrastructure, will help the automated immunoassay market stay strong in emerging nations.

Declining Reimbursement Facilities May Limit Market’s Scope in Developed Nations

On the downside, reeling under cost constraints, smaller diagnostic laboratories will find it particularly difficult to adopt automated immunoassay analyzers. Meanwhile in developed markets, the laboratories may face challenges on account of the declining reimbursements. Such factors are capable of restraining the market’s growth to an extent. Besides these, stringent regulations and the need for operating under escalating pricing pressures may adversely impact the market’s trajectory and also hamper the business flow of laboratories. Therefore, a majority of laboratories are focusing on high volume testing in order to boost profitability per test. In order to provide accurate diagnosis and perform specialized test, many of these laboratories have adopted automated systems. Such factors are likely to give the global automated immunoassay analyzers market significant impetus in the coming years.

Insulin Pumps Market Going to Rake US$9,550.7 Mn by the end of 2025

A recent intelligence study by Transparency Market Research (TMR) has detected that the global insulin pumps market is consolidated among top three companies, who accounted for more than 50% of the shares in 2016, whereas the rest of the market is fragmented, distributed among a large number of domestic and regional players. This report projects the demand in the global insulin pumps market to increment at a robust CAGR of 9.8% during the forecast period of 2017 to 2025, reaching a valuation of US$9,550.7 mn in 2025, notably up from its evaluated worth of US$4,180.4 mn in 2016.

As far as the competitive landscape is concerned, the rivalry will intensify in the near future with the influx of several new vendors. In addition to that, the existing players are expected to add to their market shares via implementation of new models as well as mergers and acquisitions. Some of the key companies currently operating in the global insulin pumps market are Cellnovo Group SA, Medtronic, F. Hoffmann-La Roche Ltd., Valeritas, Inc., Animas Corporation (Johnson & Johnson), SOOIL Developments Co., Ltd, Tandem Diabetes Care, Inc., Ypsomed AG, Insulet Corporation, and Jiangsu Delfu Co., Ltd.

Browse Full Research Report: https://www.transparencymarketresearch.com/insulin-pumps-market.html

Insulin Pumps Profitable Segment among Type-1 Diabetic Patients

Based on product, the global insulin pumps market has been segmented into insulin pumps including tethered pumps and disposable or patch insulin pumps and insulin pump supplies and accessories, which is further sub-segmented into insulin reservoirs or cartridges and infusion set insertion devices. In 2016, insulin pumps segment, with its sub-segments, collectively accounted for 70.1%, which was a reflection of several factors, such as high awareness about tethered insulin pumps among type-1 diabetes patients, growing adoption of technologically advanced products such as patch pumps, and increase in the prevalence of diabetes among the geriatric population. The report also detects that the global insulin pumps market is witnessing a preference of insulin pumps as a result of better efficiency offered by them in terms of dosage. Among distribution channel categories of hospital pharmacy, retail pharmacy, online sales, and diabetes clinics or centers, hospital pharmacy serves the maximum demand.

North America Serves Maximum Demand

Out of the five regions, North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa, studied by this report for the potential of insulin pumps market, North America is most profitable, accounting for 64.1% of the demand in 2016. The developed country of the U.S. coupled with increasing demand for advanced technology such as insulin pumps integrated with continuous monitoring system have led to the growth of insulin pumps market in the U.S., single-handedly propelling the North America market to sustain an edge over rest of the regions. Growing percentage of geriatrics, high structured healthcare sector, and availability of a well-defined reimbursement policies from public and private health insurance firms are some of the other factors helping the North America insulin pumps market.

Escalating Geriatrics Population Driving Demand

The demand in the global insulin pumps market is gaining traction from a number of factors, such as increasing prevalence of diabetes, increased focus on adult population, increasing disposable income, and growing public awareness due to the penetration of social media. On the other hand, high cost, availability of alternatives, and inadequate reimbursement policies in several emerging economies are some of the key factors challenging the insulin pumps market from attaining its true potential. Nevertheless, the vendors operating in the global insulin pumps market are expected to gain new revenue avenues from advances in insulin pumps and growing adoption against conventional methods.

Dental Implants Market Will Rake US$6.54 Bn by the end of 2025

The global dental implants market that has been analyzed in a recent research report by Transparency Market Research (TMR) demonstrates a largely consolidated vendor landscape. This is because of several large players that operate globally and a few small players that operate in regional markets.

Some of the prominent names operating in the global market for dental implants are Straumann Holding AG, Dentsply Sirona Inc., Henry Schein Inc., Zimmer Biomet Holdings Inc., 3M Health Care, Danaher Corporation, Ivoclar Vivadent AG, and AVINENT Implant System S.L.

The global dental implants market is projected to expand at a modest CAGR of 6.9% between 2017 and 2025. This will result in the market to become worth US$6.54 bn by 2025 increasing from its valuation of US$3.60 bn in 2016.

Browse Full Research Report: https://www.transparencymarketresearch.com/dental-implants-market.html

Favorable Physical Properties of Titanium Boost Demand

By product type, endosteal implants led the dental implants market in 2016 accounting for more than 80% revenue-wise. The segment is expected to grow at a significant pace in the coming years too. The segment of titanium based on material type led the market in 2016 in terms of revenue. Titanium has been witnessing high demand due to its physical properties that are suitable for dental implants.

The dental clinics end-use segment is expected to continue to dominate the global market for dental implants over the forecast period between 2017 and 2025 in terms of revenue. The clinics end-use segment held more than 60% of the market in 2016 revenue-wise.

Need to Fix Permanent Loss due to Accident, Dental Disorders Drives Market

The key factor stoking growth of the global dental implants market is an increasing number of individuals suffering from periodontal diseases across the world. For example, according to data released by the Centers for Disease Control and Prevention (CDC), 47.2% of the population above the above the age of 30 years in the U.S. is suffering from some type of periodontal disease.

“Age is a significant factor that is related to the occurrence of periodontal disorders. Tooth enamel tends to wear away with age, making the teeth susceptible to damage, dental plaques, and decay,” says an analyst at TMR. As per statistics of the World Health Organization, the elderly population across the world which stood at 524 million in 2010 is expected to reach almost 2 billion by 2050, to which developed countries such as the U.S., the U.K., Italy, and Germany will contribute significantly.

Some other growth drivers of the dental implants market are increasing prevalence of dental ailments, rising incidence of dental problems due to changing eating habits, and increasing number of accidents. In present times, changing eating habits, which includes high consumption of refined foods, due to changing lifestyle has been a significant factor for increased incidence of tooth decay at an early age.

Road accidents that account for significant number of accidents every year globally can sometimes lead to partial impairment or complete loss of body part, which includes the oral cavity. This may require a medical implant to make up for the lost body part.

Serving a roadblock to the market is the high price of dental implants and strict guidelines and regulations for the manufacture of innovative products.

Non-vascular Stents Market Will Rake US$730.5 Mn by the end of 2025

Prominent participants in the global non-vascular stents market are C. R. Bard, Inc., Boston Scientific Corporation, Cook Group Incorporated, Merit Medical Systems, Inc., Taewoong Medical Co., Ltd., Abbott Laboratories, Olympus Corporation, ELLA – CS, Medi-Globe Corporation, CONMED Corporation, M.I.TECH, and Allium Medical Solutions Ltd. At present the market is characterized by stiff competition between numerous local players and a few dominant international players. It has been noticed that the smaller local players have managed to dent shares of their global counterparts, and hence are posing a challenge to them.

As per a report by Transparency Market Research, the global non-vascular stents market will expand at a steady pace by growing at a CAGR of 5.0% from 2017 to 2025. At this rate, the market will likely become worth US$730.5 mn by 2025 from US$475.0 mn in 2016.

Browse Full Research Report: https://www.transparencymarketresearch.com/non-vascular-stents-market.html

Superior Healthcare Facilities Catapult North America Market to Forefront

Depending upon the type of products, the global non-vascular stents market can be segmented into urology stents, pulmonology stents, and gastroenterology stents. Among them, the urology stents segment is predicted to outpace all others vis-à-vis growth rate owing to growing number of kidney calculi and end-stage renal disease patients, globally. A common trend of benign prostatic hyperplasia in elderly demographics is also projected to boost growth in the segment in the next couple of years. The urology stents segment is expected to rise at a CAGR of 6.9 % between 2017 and 2025.

Geographically, the key segments of the global non-vascular stents market are North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. North America, at present, dominates the market with a leading share on account of a superior healthcare infrastructure, high healthcare expenditure per capita, high incidence of obstructive diseased patients, and favorable medical reimbursement policies of both the government and private players.

COPD Serving to Majorly Fuel Growth

At the forefront of driving demand in the global non-vascular stents market is the rising instances of chronic obstructive pulmonary disease (COPD) resulting from lung cancer, smoking, tracheobronchial malacia, and exposure to harmful chemicals. “Rising occurrence of colorectal cancer and gall stone diseases in developed countries is likely to boost the demand gastroenterology stents during forecast period. High prevalence of kidney stones and benign prostatic hyperplasia in elderly will also push up demand for global urology stents, thereby boosting the overall non-vascular stents market,” explains the lead analyst of the TMR report.

Product Development Proves Beneficial to Market

Further, growing spends on healthcare in developing countries, mushrooming hospitals and ambulatory surgical centers, and helpful medical reimbursement policies by governments and private insurance companies is also slated to catalyze growth in the global non-vascular stents market in the next couple of years. Thrust on research and development to come up with better products having improved designs, better materials, and minimally invasive stenting procedures are bolstering the market as well. The development of biodegradable stents to thwart complications of tissue in growth and stent migration is a case in point.

Proving counterproductive to the global non-vascular stents market, on the other hand, is the expensiveness of metallic stents along mandates by governments and regulatory authorities to better quality and lower process of medical devices.

Diabetic Neuropathy Market Will Rake US$5.718 Bn by the end of 2025

The global diabetic neuropathy market is semi-consolidated in which the prominent players hold limited share. The competition among the existing global and local manufacturers of diabetic neuropathy drugs is robust with most focused on research and development of better neuropathy drugs sans the complications and infections associated with their use. Boehringer, for example, has collaborated with Eli Lilly to develop new drugs to help overcome the complications caused by diabetes.

Other popular strategies leveraged by the keen leading players in the global diabetic neuropathy market are acquisitions. Novartis AG, for instance, acquired Australia-based Spinifex Pharmaceuticals, Inc., to grow its portfolio of neuropathic pain treatments.

Some of the prominent names operating in the global diabetic neuropathy market are Pfizer, Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd, and Arbor Pharmaceuticals, LLC. Pfizer, Inc., among them, leads the market due to its massive outreach and substantial spends in research and development in therapeutic areas.

As per a report by Transparency Market Research, the global diabetic neuropathy market will likely expand at a 5.4% CAGR between 2017 and 2025 to reach a value of US$5.718 bn by 2024 from US$ 3.6 bn in 2016.

Browse Full Research Report: https://www.transparencymarketresearch.com/diabetic-neuropathy-market.html

Expensiveness of Therapy Propels North America Market to Dominant Position

Depending upon the type of disorder, the global diabetic neuropathy market can be segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Among them, peripheral neuropathy accounts for maximum market share. Surpassing other segments by clocking a 5.7% CAGR from 2017 to 2025, the peripheral neuropathy is expected to hold on to its dominant position in the foreseeable future too on the back of high prevalence of diabetic neuropathy.

Based on geography, the key segments of the global diabetic neuropathy market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, of them, holds a leading share of 34.9% in the market mainly on account of the substantial number of diagnosed patients and the steep cost of therapy in the market. As a result most companies of diabetic neuropathy products are targeting the North America market.

Lifestyle Changes Trigger Market Growth

The most obvious driver of the global diabetic neuropathy market is the rising instances of diabetes caused by changing lifestyles and unhealthy dietary habits and patterns. As per WHO, about 422 were afflicted by diabetes in 2014. Other factors catalyzing growth in the market are the nod to novel drugs by FDA and other regulatory bodies and helpful reimbursement policies. “The FDA approved Nucynta ER for treating neuropathic pain caused by diabetes in 2015. Further, opioid drugs, namely morphine and methadone have also been approved to treat severe pain,” informs the lead analyst of the TMR report.

Limited Effect of Drugs Crimps Growth

Acting as a hindrance to the global diabetic neuropathy market, on the other hand, is the limited effect of therapies. Explains the lead analyst of the TMR report, “Only a quarter of patients given drugs for neuropathic pain have seen pain relief. In addition, inadequate diagnosis and incorrect understanding or selection of treatment options also serve to decrease the success of neuropathic pain treatment.” Side effects and rising cost of diabetic neuropathy treatment drugs are also serving to restrain the market.

Molecular Diagnostics Market Going to Rake US$18.9 Bn by the end of 2025

The global molecular diagnostics market is highly consolidated in nature, observes Transparency Market Research. The leading players accounted for a share of 54% in the overall market in 2015. F. Hoffman-La Roche Ltd., Abbott Laboratories, and Danaher Corporation have dominated the global market in the past few years. The broad product portfolio and strategic mergers and acquisitions have been the winning strategies of these players to remain dominant.

According to the research report, the global molecular diagnostic market is estimated to reach a valuation of US$18.9 bn by the end of 2025 as compared to US$7.1 bn in 2016. Between the forecast years of 2016 and 2025, the global market is estimated to expand at a steady CAGR of 11.6%.

Well-established Healthcare Infrastructure in North America Bodes Well for Regional Market

On the basis of technology, the global molecular diagnostics market is segmented into PCR and real-time PCR, hybridization, microarray, transcription-mediated amplification, next-generation sequencing, and others such as mass spectrometry. Of these, the PCR and real-time PCR technology segment is anticipated to show a significant progress during the forecast years. This segment is projected to expand at a CAGR of 11.1% between 2016 and 2025. The extensive usage of this technology is expected to play significant role in its growth.

On the basis of geography, the global molecular diagnostics market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. Of these, North America is estimated to account for a share of 39.6% in the overall market by the end of 2025. This segment is likely to thrive due to the changing demographics, high prevalence of cancer, evolving lifestyles, and well-established healthcare infrastructure.

Browse Full Research Report: https://www.transparencymarketresearch.com/molecular-diagnostics-industry.html

Investments in Research and Development Ensure Uptake of Molecular Diagnostic Kits

The global molecular diagnostic market is anticipated to be driven by the growing investments in research and development of biomarkers. The increasing uptake of biomarkers for diagnosis and prognosis as well as prediction and assessment of ongoing has augmented the demand for molecular diagnostics. Several kits designed for molecular diagnostics allow safe, quick, and accurate detection of infectious diseases such as HIV and hepatitis. Thus, the growing interest of big companies in expanding their business through developing biomarker solutions is expected to benefit the overall market.

The continuous evolution in the field of molecular biology has changed the way diseases are being diagnosed and treated. The new methods have the ability to detect bacteria, viruses, and genetic variations in less time in with absolute precision. Thus, the upgrades in technology, which have significantly customized health care have boosted the demand for molecular diagnostics in recent years. Analysts also predict that the wide range of technologies for diagnosis of diseases will give the global market a shot in the arm during the forecast period.

Poor Awareness and Low FDA Approvals to Restrain Market Growth

The long lead time for FDA approvals for molecular diagnostics is severely restraining the growth of the global market. Molecular diagnostics haven’t had a clinical impact on medical practice as was predicted earlier as delays in approvals have created potential hurdles. The market is also being hampered due to the poor reimbursement policies. The low awareness and lack of clarity pertaining to the diagnostic techniques used for detecting various injections and chronic conditions is a key challenge to the growth of the overall market.